Telemus Capital’s Novartis NVS Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2023
Q4 | $820K | Sell |
8,122
-1,687
| -17% | -$163K | 0.07% | 181 |
|
|
2023
Q3 | $999K | Sell |
9,809
-4,432
| -31% | -$450K | 0.09% | 154 |
|
|
2023
Q2 | $1.44M | Sell |
14,241
-762
| -5% | -$76.2K | 0.12% | 136 |
|
|
2023
Q1 | $1.38M | Sell |
15,003
-1,416
| -9% | -$124K | 0.12% | 143 |
|
|
2022
Q4 | $1.52M | Sell |
16,419
-700
| -4% | -$59K | 0.14% | 139 |
|
|
2022
Q3 | $1.3M | Sell |
17,119
-384
| -2% | -$31.8K | 0.13% | 140 |
|
|
2022
Q2 | $1.48M | Sell |
17,503
-1,114
| -6% | -$97.7K | 0.14% | 134 |
|
|
2022
Q1 | $1.63M | Sell |
18,617
-667
| -3% | -$57.8K | 0.14% | 132 |
|
|
2021
Q4 | $1.69M | Sell |
19,284
-6,423
| -25% | -$533K | 0.14% | 138 |
|
|
2021
Q3 | $2.1M | Buy |
25,707
+385
| +2% | +$34.6K | 0.18% | 110 |
|
|
2021
Q2 | $2.31M | Sell |
25,322
-2,100
| -8% | -$187K | 0.17% | 105 |
|
|
2021
Q1 | $2.39M | Buy |
27,422
+795
| +3% | +$71.3K | 0.17% | 109 |
|
|
2020
Q4 | $2.51M | Buy |
26,627
+596
| +2% | +$52.1K | 0.19% | 98 |
|
|
2020
Q3 | $2.24M | Buy |
26,031
+364
| +1% | +$31.5K | 0.16% | 110 |
|
|
2020
Q2 | $2.23M | Buy |
25,667
+23
| +0.1% | +$1.99K | 0.18% | 98 |
|
|
2020
Q1 | $2.24M | Buy |
25,644
+1,447
| +6% | +$129K | 0.18% | 100 |
|
|
2019
Q4 | $2.29M | Sell |
24,197
-12
| -0% | -$1.08K | 0.18% | 104 |
|
|
2019
Q3 | $2.1M | Sell |
24,209
-16
| -0.1% | -$1.44K | 0.17% | 111 |
|
|
2019
Q2 | $2.2M | Sell |
24,225
-3,150
| -12% | -$267K | 0.19% | 103 |
|
|
2019
Q1 | $2.36M | Buy |
27,375
+104
| +0.4% | +$8.35K | 0.18% | 111 |
|
|
2018
Q4 | $2.1M | Buy |
27,271
+693
| +3% | +$53.9K | 0.17% | 109 |
|
|
2018
Q3 | $2.05M | Sell |
26,578
-1,071
| -4% | -$79.2K | 0.15% | 117 |
|
|
2018
Q2 | $1.87M | Sell |
27,649
-716
| -3% | -$49.4K | 0.14% | 127 |
|
|
2018
Q1 | $2.06M | Sell |
28,365
-1,357
| -5% | -$103K | 0.16% | 118 |
|
|
2017
Q4 | $2.24M | Buy |
29,722
+23,267
| +360% | +$1.76M | 0.17% | 105 |
|
|
2017
Q3 | $497K | Sell |
6,455
-184
| -3% | -$13.9K | 0.06% | 207 |
|
|
2017
Q2 | $497K | Sell |
6,639
-99
| -1% | -$7.02K | 0.05% | 235 |
|
|
2017
Q1 | $448K | Sell |
6,738
-47
| -0.7% | -$3.13K | 0.05% | 236 |
|
|
2016
Q4 | $443K | Sell |
6,785
-5,180
| -43% | -$336K | 0.06% | 208 |
|
|
2016
Q3 | $847K | Sell |
11,965
-105
| -0.9% | -$7.65K | 0.09% | 159 |
|
|
2016
Q2 | $892K | Buy |
12,070
+461
| +4% | +$31.8K | 0.11% | 155 |
|
|
2016
Q1 | $754K | Buy |
+11,609
| New | +$790K | 0.13% | 149 |
|
Other funds holding NVS
Telemus Capital's NVS Position: Q4 2023 in Review
Telemus Capital reduced its Novartis (NVS) stake by 17% in Q4 2023, selling an estimated $163K and leaving 8,122 shares worth $820K. The position accounts for 0.07% of the portfolio, ranked #181.
Telemus Capital first reported a position in NVS in Q1 2016 and has held it in 32 quarters since. The position peaked at $2.51M in Q4 2020. 1,272 funds tracked by Wall St. Rank hold NVS as of Q4 2023.
- Telemus Capital held 8,122 shares of Novartis worth $820K as of Q4 2023.
- Telemus Capital sold 1,687 Novartis shares in Q4 2023, an estimated $163K.
- Novartis made up 0.07% of Telemus Capital's portfolio in Q4 2023, its #181 holding.
- Telemus Capital first reported a position in Novartis in Q1 2016 and has held it in 32 quarters since.
- Telemus Capital's Novartis position peaked at $2.51M in Q4 2020.
- 1,272 funds tracked by Wall St. Rank held Novartis as of Q4 2023.
Based on Telemus Capital's 13F filing for Q4 2023, filed 1 Feb 2024.